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An ideal human immunodeficiency virus type-1 (HIV-1) vaccine will most likely need to elicit cross-reactive neutralizing antibodies
and a strong cell-mediated immune response against multiple HIV-1 antigens to confer protection against challenge. In this study, DNA
vaccines were constructed to express virally regulated human immunodeficiency virus-like particles (VLP) to elicit broad-spectrum
immune responses to multiple HIV-1 antigens. VLPs were efficiently produced using sequences encoding gag and pol gene products from
an X4 isolate and sequences encoding for tat, rev, vpu, and env from R5 or R5X4 isolates. The integrase, vpr, vif, and nef genes were
deleted. In addition, the long terminal repeats (LTRs) were removed and transcription of the VLP insert was driven by the addition of the
cytomegalovirus immediate-early (CMV-IE) promoter. A second generation of VLP vaccine plasmids was constructed with mutations
engineered into the VLP DNA to produce particles deficient in activities associated with viral reverse transcriptase and protease. Primate
cell lines, transiently transfected with DNA, efficiently secreted VLP into the supernatant that banded within a sucrose gradient at
densities similar to infectious virions. In addition, these particles incorporated Env on the particle surface that bound soluble human CD4.
These VLPs provide a safe and efficient strategy for presenting multiple HIV-1 antigens, expressed from a single insert, to the immune
system in a structure that mimics the infectious virion.
D 2004 Elsevier Inc. All rights reserved.
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Approximately 42 million people are infected with the
human immunodeficiency virus type 1 (HIV-1) (UNAIDS,
www. unaids.org). The virus continues to spread to new
populations adding to the total number of infected individ-
uals. The use of highly active anti-retroviral therapy
(HAART) has enhanced both the longevity and quality of
life for infected individuals by controlling viral replication
(Hogg et al., 1999). Despite the effectiveness of HAART,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: tmr15@pitt.edu (T.M. Ross).several drawbacks are accompanied with this treatment that
limit its worldwide use. First, HAART neither protects
patients against initial infection, nor does HAART clear
viral infection. Second, treatment is expensive particularly
for individuals living in developing nations. Third, there can
be severe side effects and patients on HAART have
difficulties adhering to the drug regimens. Therefore, several
preventive measures to combat the spread of HIV infection
have focused on the development of safe, inexpensive, and
efficacious vaccines.
Many of the successful viral vaccines administered to
patients, such as vaccines developed for the measles or
mumps viruses, consist of replication-competent virus that
has been attenuated to prevent disease (Dorner and Barrett,
1999; Jones, 2002). The experimental use of live-attenu-
ated simian immunodeficiency virus (SIV) elicits protec-
tive immunity in nonhuman primates challenged with SIV04) 262–272
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rev gene sequences from HIV in a SIV gag–pol backbone)
infection (Kumar et al., 2000; Nilsson et al., 1998; Wyand
et al., 1999). In addition, these monkeys had specific cell-
mediated and humoral immunity that appeared to correlate
with protection. However, reversion of these vaccine
strains from attenuated to pathogenic forms resulted in
uncontrolled replication of the virus, pathogenesis, and
subsequently death of the vaccinated animals. These results
observed in nonhuman primates may have a direct bearing
on the use of live-attenuated HIV for vaccination against
infection in humans. Consequently, this approach is not
considered a viable vaccine strategy for preventing HIV or
AIDS.
The development of DNA vaccine (genetic vaccine)
technology has opened new avenues for AIDS vaccine
research. These genetic vaccines consist of eukaryotic
expression plasmids that are inoculated into target cells of
a vaccinated host and subsequently translated into protein
(Donnelly et al., 1998). DNA plasmids inoculated in vivo,
expressing a gene insert, elicit protective immunity against a
variety of pathogens (Liu et al., 1998; Robinson, 1997;
Robinson and Pertmer, 2000). Similar to live-attenuated
virus, DNA vaccines expressing lentiviral antigens elicit
both high titer antibody and cell-mediated immune
responses to HIV–SIV in both rodents and nonhuman
primates (Kim et al., 2001; O’Neill et al., 2002). Therefore,
administration of DNA plasmid is an alternative strategy to
the use of live-attenuated virus.
The induction of a broad range of immune responses
appears necessary for any vaccine strategy against HIV
or AIDS (Spearman, 2003). A predominately antibody-
mediated immune response does not confer protection
against HIV infection (Mascola, 2003). Nonhuman
primates vaccinated with plasmids expressing HIV or
SIV antigens had high-titer, anti-viral antibodies but were
unable to control viral challenge (Muthumani et al.,
2003; Warren, 2002). In preclinical human trials,
volunteers vaccinated with recombinant Envgp120 or
Envgp160 elicited transient, non-neutralizing anti-Env
antibodies that did not result in long-term immune
memory (Lindenburg et al., 2000; Pitisuttithum et al.,
2003). However, an exclusively cell-mediated immune
response against HIV–SIV antigens also does not appear
to correlate with long-term protective immunity (Amara
et al., 2002a). Vaccine strategies that elicit both humoral
and cell-mediated immunity appear to be crucial in
limiting viral replication and protection from live virus
infection. Monkeys primed with DNA expressing Gag–
Pol and Env, followed by a vector boost of modified
vaccinia Ankara (MVA) expressing the same antigens,
were able to control viral replication more effectively
than those animals vaccinated with only Gag–Pol (Amara
et al., 2002a). These results highlight the importance of
immune responses to Env, as well as to Gag–Pol, in
controlling immunodeficiency virus challenges. In thepresent study, a DNA vaccine was constructed to express
a virally regulated human immunodeficiency virus-like
particle (VLP) to elicit broad-spectrum immune responses
to multiple HIV-1 antigens. These VLPs were engineered
with specific safety mutations and deletions in the
genome to prevent integration, severely restrict RNA
genome packaging, as well as inhibit reverse tran-
scriptase and protease activity.Results
Construction of plasmids expressing human
immunodeficiency virus-like particles
In this study, a virus-like particle (VLP) was developed
to elicit broad spectrum immune responses to a variety of
HIV-1 antigens. The proviral plasmid pHIV-1BH-10, which
encodes for a CXCR4-utilizing virus, was used as a
template to construct plasmids expressing VLP. A deletion
was introduced into pHIV-1BH-10 by cloning of two PCR
products encompassing (1) the regions encoding for gag–
pol and (2) the vpu, env, rev, and tat genes (Fig. 1), which
resulted in the deletion of sequences encoding integrase,
vif, vpr, and nef. In addition, both long terminal repeats
(LTRs) were removed. The final plasmid pVLPBH10
expresses the capsid, matrix, nucleocapsid, protease,
reverse transcriptase, envelope, Vpu, Tat, and Rev from
HIV-1BH10.
The pVLP89.6 plasmid was constructed by first making
two subclones encoding for the 5Vend of the VLP gene
insert (gag–pol region) and a second subclone encoding
for the 3Vend of the VLP gene insert (vpu, env, tat, and
rev). Oligonucleotides were used to amplify each fragment
that was then subcloned into the expression vector
pTR600. The two fragments were cloned together into a
single VLP gene insert (Fig. 1). Moreover, two additional
3VPCR products were constructed using sequences from
clade B viruses. Each 3V PCR product, encoding the env
sequences from two R5 HIV-1 isolates ADA and R2 (a
kind gift from Gerald Quinnan), was cloned with the 5V
PCR product encoding for the gag–pol sequences from
HIV-1BH10. Lastly, safety mutations were introduced in the
VLP DNA using site-directed mutagenesis to increase
vaccine safety for potential use in humans. These
mutations were designed to disable the encapsidation of
viral RNA (C15S, C36S) (Lowe et al., 1991), abrogate
RNase H activity (D185N, W266T, E478Q) (Chao et al.,
1995; Le Grice et al., 1991; Mizrahi et al., 1994;
Yamamoto et al., 1996), and inactivate the viral protease
(D25N) (Babe et al., 1995; Kohl et al., 1988).
The phGag and phGag–Pol (generously donated by
Gary Nabel) express core structural and enzymatic proteins
from a codon-optimized gene insert (Huang et al., 2001).
Each of these plasmids encodes for the Gag and Pol gene
products using an X4 isolate as the pVLP plasmids (Fig.
Fig. 1. Schematic representation of DNA vaccine constructs. Panel A: wild-type, proviral DNA; Panel B: VLP DNA with regions encoding for the 5V PCR
product (HIV-1BH10: p17, p24, p15, PR, RT) and the 3V PCR product (HIV-1ADA, 89.6, or R2: vpu, env, rev, tat); Panel C: Gag–Pol DNA; Panel D: Gag DNA.
Restriction sites are based on the nucleotide sequence for HIVBH-10. * Represents mutations in NC. ! Represents mutations in PR. X Represents mutations in RT.
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the pVLP and pVLP(D25N) plasmids.
In vitro expression of human immunodeficiency virus-like
particles
Each VLP expressing plasmid was verified for expression
in monkey COS (Fig. 2) or human 293T cell lines (data not
shown). Vaccine plasmids expressing VLP with RT and NC
safety mutations, but without the protease mutation,
expressed Gag and Pol gene products that were detected in
both the cell lysates and supernatants of transiently trans-
fected cells (Figs. 2A and B). Unprocessed Gag–Pol gene
products (Gag–Polp160, Gagp55, Gagp41) were detected
primarily in the cell lysate fraction compared to the super-
natant (Figs. 2A and B), whereas Gagp24 was detected in both
the cell lysates and supernatants. Similar results were
observed from cells transfected with phGag–Pol (Figs. 2E
and F). DNA expressing VLP with no safety mutations had
similar expression patterns (data not shown). In contrast,
DNA expressing VLPD25N expressed incompletely processed
Gag–Pol gene products (Gagp160, Gagp55, Gagp41) (Figs. 2C
and D). Fully processed Gagp24 or Gagp17 gene products were
not detected in supernatants or cell lysates from cells
transiently transfected with DNA expressing VLP with the
PRD25N (VLPD25N) mutation. These results were similar to
cells transfected with phGag or phGag–PolD25N (Figs. 2E and
F). Env was detected in the supernatant of cells (1–2 ng/ml)
transfected with DNA expressing VLP and was not affected
by the introduction of safetymutations. Therefore, each of the
DNA plasmids expressing virus-like particles efficiently
expressed all the structural VLP gene products.Particles were purified from the supernatants of
transiently transfected cells by ultracentrifugation (20–
60% sucrose gradient) and collected fractions were
analyzed for particle composition and stability. Super-
natants from cells transfected with DNA expressing VLP
contained particles that banded between 32% and 40%
sucrose (1.14–1.18 g/cm3) (Fig. 3). These virus-like
particles banded in a sucrose gradient similar to wild-
type virions (Dettenhofer and Yu, 1999; Mouland et al.,
2000; Tang et al., 2003; Wang et al., 1998). Gagp55,
Gagp41, and Gagp24 were readily detectable in each of
these fractions. All VLPs banded in the same percentage
of sucrose regardless if they were expressed from DNA
encoding VLP with or without the safety mutations (Fig.
3). However, supernatants from cells transfected with
DNA expressing VLP with the PRD25N mutation had
particles without detectable levels of Gagp24 (Fig. 3B).
Similar results were observed from cells transfected with
phGag–Pol incorporating the PRD25N (data not shown).
However, cells transfected with the phGag–Pol plasmid
produced particles that contained predominately processed
Gag gene products with little higher molecular weight
Gag–Pol proteins, whereas cells transfected with phGag–
DNA had unprocessed gene products (Figs. 3C and D).
Although each DNA plasmid efficiently expressed VLP,
the composition of the particles differed depending on
protease activity.
Accessory protein activity
Rev activity was not measured directly, but was observed
as a result of structural HIV-1 antigen expression and
Fig. 2. Expression of vaccine constructs in vitro. COS cells were transfected with 2 Ag of each vaccine plasmid. Samples were electrophoresis on a 10%
Western blot (2.0% of cell lysate and 1.0% of supernatant). Panels A and B VLP with NC and RT safety mutations; lane 1, pTR600 vector; lane 2, pVLP89.6;
lane 3, pVLPADA; and lane 4, pVLPR2. Panels C and D: VLP with NC and RT safety mutations and protease mutation; lane 1, pVLPADA; lane 2,
pVLPADA(D25N); lane 3, pHIV-1R2; and lane 4, pHIV-1R2(D25N). Panels E and F: phGag or phGag–Pol VLP; lane 1, phGagp55; lane 2, phGag–Polp160; and lane
3, phGag–Pol(D25N). Panels A, C, and E: cell lysates. Panels B, D, and F: supernatants.
K.R. Young et al. / Virology 327 (2004) 262–272 265particle formation. VLPs secreted into the supernatant of
transfected cells indicate that Rev actively promoted the
cytoplasmic accumulation of mRNA transcripts encoding
for structural gene products (Cullen, 2003). In addition,
DNA expressing infectious virions or VLP had similar
levels of Tat activity as observed directly using a secreted
alkaline phosphatase (SEAP) reporter assay (Berger et al.,
1988). COS cells were transfected with DNA expressing
infectious virions or VLP, as well as a reporter plasmid
containing HIV-1 LTR-SEAP. The level of Tat activation of
the LTR was similar regardless whether Tat was expressed
from proviral DNA (pHIVADA) or DNA encoding VLP
(Table 1). Therefore, DNA encoding VLP transcribed
mRNA that efficiently expressed functional Tat and Rev
molecules.
Envelope on the surface of VLP binds the human CD4
molecule
VLP, expressed from DNA plasmid, bound soluble
human CD4 (sCD4) (Fig. 4). VLPs secreted into the
supernatant of COS cells were incubated with a soluble
form of human CD4. Each VLP, with Env89.6, EnvADA, orEnvR2 on the surface, bound sCD4 with similar efficiency
to wild-type, infectious HIV-1 (Fig. 4). Only VLP
containing envelope, not Gag only particles, bound sCD4
indicating that the interaction was specific to particles
incorporating Env. In addition, cells transfected with a
plasmid expressing gp12089.6 only did not bind to sCD4
because monomeric gp120 was not able to transverse the
20% glycerol layer during purification. Interestingly, even
though the EnvR2 on the VLP binds CCR5 independent of
CD4 (unpublished observations), the EnvR2 on the surface
of the VLP bound CD4 with equal efficiency as CD4-
dependent envelopes.Discussion
In this study, a molecular clone was constructed to
express a human immunodeficiency virus-like particle as a
potential vaccine candidate. The composition of the
expressed particle has properties that distinguish it from
the many VLP for HIV-1 currently in preclinical trials (for
reviews, please see Hardy et al., 2002; Spearman, 2003;
Stevceva and Strober, 2004; Yao et al., 2003; Young and
Fig. 3. Comparison of sedimentation patterns of secreted viral proteins by sucrose density-equilibrium gradient analysis. Supernatants from COS cells
transiently transfected with plasmid DNA were concentrated through a 20% glycerol cushion and then subjected to 20–60% sucrose density-equilibrium
gradient centrifugation. Fractions were collected (ten 1-ml aliquots) from the top of the gradient. Fractions were examined by Western analysis. Proteins were
probed with HIV-Ig (1:5000) and mouse antihuman IgG (1:7000), and visualized by enhanced chemiluminescence. Panel A: pVLPR2, panel B: pVLPR2(D25N),
panel C: phGagp55, panel D: phGag–Polp160. Percent of sucrose fraction is located at the bottom of each lane: lane 1, 20%; lane 2, 24%; lane 3, 28%; lane 4,
32%; lane 5, 36%; lane 6, 40%; lane 7, 44%; lane 8, 48%; lane 9, 52%.
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were expressed from more than one plasmid or the
expressed particles were purified and used as an inoculum
(Boyer et al., 1998; Buonaguro et al., 2002; Haigwood et
al., 1999; Huang et al., 2001; Jaffy et al., 2004; Kang and
Compans, 2003; Kim et al., 1997; Wang et al., 2000; Yao
et al., 2002). Lentiviral particles, expressed from a single
DNA plasmid or from modified vaccinia Ankara (MVA)
and inoculated into nonhuman primates, elicited a broad
immune response to the expressed antigens (Amara et al.,
2002a, 2002b; Buge et al., 2003). The virus-like particles
expressed from plasmids described in this report can be
purified and used as an inoculum or the VLP can be
expressed from DNA plasmid or viral vectors in vivo. The
genome of the VLP contains deletions encompassing the
integrase, vif, vpr, and nef genes, as well as the 5Vand 3V
long terminal repeats of HIV-1 (Fig. 1). The VLP wasTable 1
Induction of Tat activity
Plasmid Relative percentage of Tat activitya
pLTR-SEAP 7.0 F 1.3
pGag–Pol 7.5 F 0.9
pVLPADA 100.0 F 0.0
pVLP89.6 100.0 F 0.0
pVLPR2 87.0 F 8.5
pHIV-189.6 100.0 F 0.0
a Percent of Tat activity relative to pHIV-189.6.encoded by the HIV-1 gag, pol, vpu, env, rev, and tat gene
sequences. The deletion of integrase and each viral LTR
inhibits the ability of any potential VLP or proviral DNA
from inserting into host cell chromosomes (Fletcher et al.,
1997). The accessory genes (vpr, vif, and nef) have
immunomodulatory effects on the immune system (Ander-
son and Hope, 2003), which may be deleterious for HIV
vaccine development and were therefore removed. VLP
DNA efficiently expressed the structural gene products (Fig.
2) and secreted particles into the supernatant of transiently
transfected cells (Fig. 3). The regulatory proteins (Tat and
Rev) were efficiently expressed and had similar levels of
activity as proteins expressed from proviral DNA (Table 1).Fig. 4. VLP binding to soluble human CD4 (hCD4). Culture supernatants
from COS cells transfected with plasmid DNA were incubated with
supernatants from cells expressing sCD4 for 4 h and then pelleted through a
20% sucrose cushion followed by Western hybridization analysis. Proteins
were probed with rabbit polyclonal anti-hCD4 (1:3000). Antibody bound
protein was detected by goat anti-rabbit IgG (1:5000) and visualized by
enhanced chemiluminescence. Lane 1, pTR600 vector; lane 2, purified
sCD4 control; lane 3, phGag–Pol; lane 4, pVLP89.6; lane 5, pVLPR2; lane 6,
pVLPADA; and lane 7, pHIV-189.6.
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constructed that contained a substitution in the region
encoding for env. DNA gene segments encoding for env,
as well as tat, rev, and vpu, were cloned into the VLP
DNA backbone (Fig. 1). The env gene segments were
cloned from one R5X4 (89.6) and two R5 isolates (ADA
and R2). The ADA, along with the original 89.6 env
genes, was selected for two reasons: (1) each envelope is
currently being used by several research groups for HIV
vaccine development and therefore would be useful for
comparison of elicited immune responses, and (2) X4
envelopes, such as the Env derived from the HIV-1BH10 or
HIV-1IIIB isolates, are more sensitive to neutralizing
antibody compared to primary R5 isolates (Crawford et
al., 1999; Means et al., 1997). The EnvADA is a
particularly difficult envelope to neutralize and therefore,
vaccine strategies that elicit neutralizing antibodies using
VLP expressing this envelope may elicit a broader immune
response to a diverse set of HIV-1 isolates. EnvR2, cloned
from a patient isolate (HNS2), can be neutralized by sera
from patients infected with HIV-1 from clades A, B, C, D,
and F, as well as circulating recombinant forms (CRF)
(Quinnan et al., 1999), and was therefore selected for use
as an Env immunogen in the VLP. Virions pseudotyped
with the EnvR2 can mediate CD4-independent infection. In
addition, these viruses are sensitive to neutralization by a
panel of monoclonal antibodies that recognize conforma-
tion-dependent epitopes in envelope (Zhang et al., 2002).
Recently, Dong et al. (2003) demonstrated that the EnvR2,
expressed from a VEE replicon, elicited high titer
neutralizing antibodies. Therefore, the 89.6, ADA, or R2
envelopes, incorporated on the surface of the VLP, each
has advantages for enhancing the effectiveness of the VLP
immunogen.
One advantage of incorporating viral envelope glyco-
proteins on the surface of the VLP is the presentation of Env
in a native conformation. The inoculation of monomeric
Envgp120 elicits high titer anti-Env antibody that does not
prevent viral entry into susceptible cells. Various approaches
to construct soluble trimeric forms of Env that more closely
mimic the native Envgp160 on the surface of virions have
been employed. Soluble trimerized Envgp140, unstabilized or
stabilized with domains (GCN4 or the T4 bacteriophage
fibritin motifs or by disulfide linkers) (Abrahamyan et al.,
2003; Bower et al., 2004; Sanders et al., 2000, 2002;
Schulke et al., 2002; Yang et al., 2000, 2002), elicited
modest levels of enhancement of neutralizing antibody
compared to antibody elicited by monomeric forms of Env.
However, even though many of these approaches use a
trimerized envelope, there are still distinct differences
between soluble, trimerized Env and the structure of native
trimeric form of Env anchored on the surface of the virion.
Therefore, the expression of Env in the context of a particle
may prove advantageous for vaccine development.
The potential of the VLP RNA to recombine with an
HIV-1 genome in an infected patient could limit the useof this vaccine in humans. Therefore, a third generation
of VLP expressing plasmids was constructed that
incorporated a variety of mutations to increase the safety
of these vaccines for potential use in humans. The VLP
was modified to prevent (1) the packaging of RNA, (2)
reverse transcriptase activity, and (3) the proteolytic
processing of Gag–Pol polypeptides. The first set of
mutations, introduced into the nucleocapsid (NC) coding
region, disrupts the two zinc finger motifs (Mizuno et al.,
1996). The principal function of the NC involves the
specific encapsidation of full-length, unspliced (genomic)
RNA into virions. Introduction of serine residues at
positions 15 and 36 in the NC prevents the binding of
zinc and disrupted zinc finger formation in the NC.
Previous studies have demonstrated severely restricted
packaging of genome RNA into both infectious virus as
well as VLP incorporating these NC mutations (Akahata
et al., 2000, 2003a, 2003b; Ellenberger et al., 2004;
Mizuno et al., 1996; Yovandich et al., 2001).
During the process of reverse transcription, the viral
RNA is converted into proviral DNA in a series of
defined steps (Acheampong et al., 2003; Freed, 2001).
RT activity could have been eliminated by the deletion of
the gene sequences encoding for RT. However, at least
seven epitopes in RT are immunogenic and are advanta-
geous for eliciting anti-viral immunity (Huang et al.,
1995). The introduction of recombinant HIV-1 RT elicited
high-titer CTL responses (Menendez-Arias et al., 1998).
Therefore, we choose to disrupt RT activity without
preventing the expression of this protein (Ellenberger et
al., 2004) and thus the presentation of RT epitopes to the
immune system.
The final mutation substituted an asparagine for
aspartic acid residue at position 25 in protease. Previous
studies have shown that cells transfected with DNA
expressing lentiviral VLP with a mutation at amino acid
25 in PR expressed a precursor molecule with high levels
of unprocessed Gag proteins (Ellenberger et al., 2004;
Park and Morrow, 1991; Smith et al., 1993). Nonetheless,
this precursor molecule can be incorporated into a
particle through its interactions with the capsid domain
of Gag (Huang et al., 1995). The viral protease, similar
to other aspartyl proteases, such as renin and pepsin,
contains the conserved asparagine–threonine–glycine
sequence (protease amino acid positions 25–27) in the
active site. The initial critical step for autoprocessing of
the Gag–Pol precursor protein is the folding and
dimerization of this protein leading to the formation of
the active site. A substitution of an asparagine residue at
this position prevents this folding and therefore results in
loss of enzymatic activity without an effect on protein
structure, which allows for an accumulation of unpro-
cessed Gagp55 and Gag–Polp160 in the cell lysate and
supernatants (Fig 3B). Live virus particles that are
expressed from proviral DNA and contain the PRD25N
are noninfectious (Babe et al., 1995). In addition, co-
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PRD25N resulted in a dose-dependent decrease in particle
maturation and infectivity (Babe et al., 1995). Therefore,
expression of these VLP vaccines in an infected patient
could have the additional benefit of reducing the
infectivity of the wild-type virions.
Infection with live virus results in virions containing
Gag polyproteins that are fully processed during matura-
tion post-budding. These particles are mature and
composed of a dense capsid core and contain multiple
viral proteins within the particle that are associated with
the genomic RNA. In addition, human immunodeficiency
virus-like particles are composed of immature particles
with mostly processed Gag gene products and have
severely reduced levels of VLP-RNA packaging (Ellen-
berger et al., 2004). In contrast, VLPD25N is composed of
surface envelope on primarily unprocessed Gagp160 and
Gagp55 (Fig. 3B). Each of these various particles may have
advantages for eliciting a broad range of immune responses.
The particles described in this report have distinct
advantages for vaccine development. First, the deletion of
the viral LTR, integrase, vpr, vif, and nef sequences
enhances the safety of the vaccine and reduces the
immunomodulatory effects of the immunogen. The
introduction of mutations in RT and the NC further
increases the safety of this vaccine by reducing the
infectivity of these particles. Most live or live-attenuated
viruses contain viral RNA and are therefore replication
competent with the ability to produce pathogenesis in
vaccinated hosts. The lack of particle-encapsidated RNA
and the inability of the vaccine insert to integrate into
host chromosomes are advantages of this VLP vaccine
(Engelman and Craigie, 1992; Engelman et al., 1995;
Lowe et al., 1991; Mizuno et al., 1996). A second
advantage is that all of the HIV-1 gene products can be
expressed from a single DNA plasmid. The ability to
characterize one DNA plasmid expressing the entire VLP
reduces the potential regulatory and safety concerns
associated with testing multiple DNA plasmids for
prospective use in humans. Third, VLPD25N produces
particles with predominately unprocessed, higher molec-
ular weight Gag gene products that may elicit higher
levels of anti-HIV CTL responses compared to particles
with fully processed Gag gene products. Recently, it was
demonstrated that splenocytes from mice vaccinated with
particles composed of Gagp55 lysed a higher number of
target cells, presenting Gag peptides, compared to cells
from mice vaccinated with particles composed of Gag–
Polp160 (Huang et al., 2001). Fourth, the inactivation of
the viral protease may lead to markedly reduced shedding
of gp120 (Hammonds et al., 2003). Human CD4
interaction increases shedding of gp120 from viral
particles and gp120 may also be lost from VLP during
particle purification procedures (Hart et al., 1991;
McKeating et al., 1991; Moore et al., 1993). Thus,
VLPD25N has the added advantage of retaining Env andthereby increasing anti-Env immune responses. Lastly, the
VLPs described in this report have the added advantage
of presenting Env epitopes to the immune system and
therefore eliciting both a broad spectrum antibody and
cell-mediated immune response.
An effective vaccine against HIV or AIDS will most
likely need to elicit high levels of cross-reactive
neutralizing antibodies in combination with a robust
cell-mediated response against multiple viral antigens to
protect from disease in an infected host. One approach to
achieve these goals is the development of a human
immunodeficiency virus-like particle. In general, these
particle-based strategies present multiple viral proteins in
a conformation similar to the live virus without the safety
issues associated with replication-competent virions.
Current virus-like particle vaccines are similar in nature
to live-attenuated viruses, expressing both structural and
enzymatic proteins. The virus-like particle vaccine
described in this study does not produce a productive
infection or integrate into host chromosomes. The non-
replicative nature of this type of vaccine prohibits the
particles from reverting or recombining with wild-type
vRNA to produce to a pathogenic form. The incorpo-
ration of additional safety mutations enhances the value
of these vaccines for use in humans.Materials and methods
DNA Plasmids
The vaccine plasmid pTR600 has been previously
described (Green et al., 2003). Briefly, the vector was
constructed to contain the cytomegalovirus immediate-
early promoter (CMV-IE) for initiating transcription of
eukaryotic inserts and the bovine growth hormone
polyadenylation signal (BGH poly A) for termination
of transcription. The vector contains the Col E1 origin
of replication for prokaryotic replication and the
kanamycin resistance gene (kanr) for selection in
antibiotic media.
The parental plasmid pHIV-1BH10 (accession number
M1564) encodes the sequences from the proviral HIV-1
isolate BH10 (X4) and was used as a template to construct
the plasmid pVLPBH10 (Fig. 1). A second plasmid pVLP89.6
expressed a VLP with the Env region encoded from the
isolate 89.6 (accession number U39362). The pVLP89.6
plasmid encodes for the following gene sequences: HIV-
1BH10 gag–pol (pHIVBH10 nt 112–3626) and HIV-189.6 vpu,
env, rev, tat (pHIVBH10 nt 5101–8159).
The pVLP89.6 was constructed from two subclones
encoding for the 5V end of the VLP gene insert and a
second subclone encoding for the 3V end of the VLP
gene insert (Fig. 1). Oligonucleotides corresponding to
the gag–pol sequences were used in a PCR reaction to
amplify a fragment of DNA (5V PCR product) composed
Table 2
Oligonucleotide pairs used for mutagenesis
Nucleocapsid (NC)
C15S (pHIVBH10, nt 1285) (Mizuno et al., 1996)
sense primer 5Vggttaagagcttcaatagcggcaaagaagggc3V
antisense primer 5Vgcccttctttgccgctattgaagctcttaacc3V
C36S (pHIVBH10, nt 1357) (Lowe et al., 1991)
sense primer 5Vgggcagctggaaaagcggaaaggaagg3V
antisense primer 5Vccttcctttccgcttttccagctgccc3V
Polymerase (Pol)
D185N (pHIVBH10, nt 2460) (Chao et al., 1995)
sense primer 5V-ccagacatagttatctatcaatacatgaacgattgtatgtagg-3V
antisense primer 5V-cctacatacaaatcgttcatgtattgatagataactatgtctgg-3V
W266T (pHIVBH10, nt 2703) (Le Grice et al., 1991)
sense primer 5V-ggggaaattgaataccgcaagtcagatttaccc-3V
antisense primer 5V-gggtaaatctgacttgcggtattcaatttcccc-3V
E478Q (pHIVBH10, nt 3339) (Yamamoto et al., 1996)
sense primer 5V-ccctaactaacacaacaaatcagaaaactcagttacagc-3V
antisense primer 5V-gcttgtaactgagttttctgatttgttgtgttagttaggg-3V
Protease (PR)
D25N (pHIVBH10, nt 1683) (Babe et al., 1995)
sense primer 5V-ggaagctctattaaatacaggagcagatg-3V
antisense primer 5V-catctgctcctgtatttaatagagcttcc-3V
Underlined codons represent mutations introduced into each gene sequence.
K.R. Young et al. / Virology 327 (2004) 262–272 269of the 5V untranslated leader sequence (105 nucleotides)
and gag–pol sequences (start codon of gag to the TAG
stop codon at the 3V end of the reverse transcriptase
sequence, pHIVBH10 nt 112–3626). For the 5V PCR
product, a ClaI restriction enzyme site was introduced
(pHIVBH10, nt 1) at the 5V end of the vaccine insert,
while an EcoRI (pHIVBH10, nt 3626) and NheI site
(pHIVBH10, nt 8159) were added at the 3V end of the 5V
PCR product by PCR. The following primers were used
to amplify the 5V PCR product: sense primer 5V-
gagctctatcgatgcaggactcggcttgc-3V and antisense primer
5V-ggcaggttttaatcgctagcctatgaattcc-3V. The 3V PCR product
was a DNA fragment encoding the vpu, env, rev, and tat
genes and the appropriate splice acceptor sites. An EcoRI
site was introduced into the 5V terminus of the 3V PCR
product (pHIVBH10 nt 5101) and an NheI site was
introduced at the 3V terminus (pHIVBH10 nt 8159) and
the 3V PCR product was amplified by the following
primers: sense primer 5V-cccaccttaagacgttgttgacgacaaa-
tacg-3Vand antisense primer 5V-ccacactactttcggaccgctagc-
caccc-3V. Both of the 5Vand 3VPCR products were cloned
into pTR600 using unique restriction enzymes sites (5V
PCR product: ClaI and EcoRI and the 3V PCR product
using EcoRI and NheI). The resulting plasmid pVLP89.6
encodes for a virus-like particle.
Two additional VLP expressing DNA plasmids were
constructed that encoded for various env sequences. The
vpu, env, rev, and tat sequences were cloned by PCR
amplification from the proviral DNA from the HIV-1
isolates ADA or R2 and each PCR fragment was
inserted into the pVLP89.6 Gag–Pol backbone using
unique EcoRI and BamHI restriction sites (Fig. 1). The
splice–acceptor sites were not mutated to allow for
efficient mRNA processing of singly and multiply
spliced messenger RNAs.
psCD4 contains the soluble human CD4 gene (four
extracellular domains) and was cloned into pTR600 using
unique restriction sites HindIII and NheI (sense primer 5V-
gtcagcaagcttatgaaccggggagtcc-3Vand antisense primer 5V-
gctgacgctagcgctacctcctccgcctccatcgatgctacctccgcctccgc-
tacctccgccgcttccgaattcggtggaccatgtg-3V). The plasmids
pGagp55 and pGagp160 are derived from codon-optimized
sequences (hGag and hGag–Pol, respectively) previously
described (Huang et al., 2001). Sequences encoding for
Gagp55 and Gag–Polp160 (pHIVBH10, nt 112–1644 and
112–4552, respectively) were cloned from phGag and
phGag–Pol (generously donated by Gary Nabel) into
pTR600 using unique restrictions sites HindIII and
BamHI.
The plasmids were amplified in Escherichia coli
strain-DH5 alpha, purified using anion-exchange resin
columns (Qiagen, Valencia, CA), and stored at 20 8C in
dH2O. Plasmids were verified by appropriate restriction
enzyme digestion and gel electrophoresis. Purity of DNA
preparations was determined by optical density reading at
260 and 280 nm.Safety mutations
Safety mutations were introduced into the VLP vaccine
inserts or phGag–Pol by PCR-based mutagenesis (Strata-
gene, La Jolla, CA) (Table 2). All mutations were verified
by sequencing.Transfections and expression analysis
The monkey fibroblast cell line COS (5  105 cells/
transfection) was transfected with 2 Ag of DNA using 12%
lipofectamine according to the manufacturer’s guidelines
(Life Technologies, Grand Island, NY). Supernatants (2 ml)
were collected and stored at 20 8C. Cell lysates were
collected in 500 Al of 1% Triton X-100 and stored at20 8C.
Quantitative antigen capture ELISAs were conducted accord-
ing to the manufacturer’s protocol (Perkin-Elmer Life
Sciences, Boston, MA).
For Western hybridization analysis, 3.3% of supernatant
and 1.5% of the cell lysate were diluted 1:2 in SDS sample
buffer (Bio-Rad, Hercules, CA), boiled for 5 min, and loaded
onto a 10% polyacrylamide/SDS gel. The resolved proteins
were transferred onto a nitrocellulose membrane (Bio-Rad)
and incubated with a 1:5000 dilution of polyclonal human
HIV-infected patient antisera (HIV-Ig) in PBS containing
0.05% Tween 20 and 5% nonfat dry milk. After extensive
washing, bound human antibodies were detected using a
1:7000 dilution of horseradish peroxidase-conjugated goat
antihuman antiserum and enhanced chemiluminescence
(Amersham, Buckinghamshire, UK).
For determination of Tat activity, COS cells (5 105) were
transiently transfected using 12% lipofectamine in DMEM
K.R. Young et al. / Virology 327 (2004) 262–272270with 1 Ag of each VLP DNA and 1 Ag of the reporter plasmid
pLTR-SEAP (Berger et al., 1988). After 18 h, cells were
replenished with fresh media (1.5 ml) and incubated an
additional 48 h. Collected supernatants (100 Al) were
incubated with 100 Al of SEAP buffer (2 M diethanolamine,
1 mM MgCl2, 20 mM l-homoarginine) for 10 min at 37 8C
followed by the addition of 20 Al p-nitrophenyl phosphate
(120 mM) (PNP) (Sigma, St. Louis, MO) for 30 min at 37 8C.
Samples were analyzed for color change at 405 nm. Data
were recorded as the average of the three independent
experiments F standard deviation.
Purification of virus-like particles
Supernatants from COS cells, transiently transfected with
plasmid expressing Gag, Gag–Pol, VLP, or infectious virions,
were pelleted via ultracentrifugation (100000  g through
20% glycerol, weight per volume) for 2 h at 4 8C. The pellets
were subsequently resuspended in PBS and overlaid onto 20–
60% sucrose gradients (11 steps, 4% increments) and
ultracentrifuged for 17 h at 100000  g at 4 8C. Eleven
fractions (20–60%, 1 ml, weight per volume) were collected
top to bottom from the gradient, and the proteins were
precipitated with equal volumes of 20% trichloroacetic acid
(TCA) and subjected to SDS-PAGE and immunoblotting.
The viral proteins were detected by HIV-Ig via Western
hybridization.
VLP binding to human CD4
Supernatants from COS cells transiently transfected with
plasmids expressing VLP, infectious virions, or Gag–Pol
were incubated at RT for 4 h with supernatants from COS
cells transiently transfected with a plasmid expressing soluble
human CD4 (sCD4) (9:1 ratio). The mixture (10 ml) was
centrifuged (100000 g) and pelleted through 20% sucrose.
Each pellet was resuspended in PBS and analyzed byWestern
hybridization for CD4 bound to VLP. sCD4 was detected by
mouse polyclonal anti-CD4 (1:3000) followed by goat anti-
mouse IgG conjugated to HRP (1:7000) (Bio-Rad). The
proteins were enhanced by chemiluminescence and visual-
ized by autoradiography.Acknowledgments
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